E Fund Management’s Lineage Cell Therapeutics LCTX Stock Holding History

E Fund Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,095	Closed	-$28K	–	307
2021 Q3	$28K	Buy	+11,095	New	+$28.5K	﹤0.01%	271

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

E Fund Management's LCTX Position: Q4 2021 in Review

E Fund Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 11,095 shares — an estimated $28K sold.

E Fund Management first reported a position in LCTX in Q3 2021 and held it in 1 quarter. The position peaked at $28K in Q3 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

E Fund Management reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
E Fund Management sold 11,095 Lineage Cell Therapeutics shares in Q4 2021, an estimated $28K.
E Fund Management first reported a position in Lineage Cell Therapeutics in Q3 2021 and held it in 1 quarter.
E Fund Management's Lineage Cell Therapeutics position peaked at $28K in Q3 2021.
124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on E Fund Management's 13F filing for Q4 2021, filed 11 Feb 2022.